Hyperkinesia

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024
Research, ARIA, FLNA, Drug development, ADAS, Exercise, ADAS-Cog, Private law, Mass spectrometry, Criterion, CDR, Bawskee 3.5, Protein, Intellectual property, Patient, Plasma, Cassava Sciences, PET, MRI, City University, Hyperkinesia, Cerebrospinal fluid, Edema, Cassava, Memory, Insulin, G&A, Tablet, Brain, City, CUNY, SAP, Calendar, Completion, Safety, Clinical, Knowledge, Alzheimer's disease, Magnetic resonance imaging, Blood, FDA, Ageing, Food, Data, Lymphocyte, Medicine, DSMB, Pharmaceutical industry

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.

AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Retrieved on: 
Tuesday, January 9, 2024
Senior, Family, Development, Dyskinesia, Hyperkinesia, Patient, European, Dementia, MD, Uncertainty, ABBV, Cellulitis, University, Parkinson's disease, PD, Disability, Aes, Tremor, Hypertonia, University of Padua, Movement, Safety, L-DOPA, Doctor of Philosophy, Neurology, AbbVie, Edema, Hallucination, Hypokinesia, Pharmaceutical industry

NORTH CHICAGO, Ill., Jan. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the launch of PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement), and when available combinations of Parkinson's medicinal products have not given satisfactory results.1

Key Points: 
  • The VYAFUSER™ pump for the subcutaneous delivery of PRODUODOPA received Conformité Européenne (CE) Mark in November of 2023.
  • Parkinson's disease is a chronic, progressive neurodegenerative disorder affecting approximately 6.1 million people globally3 and is expected to double by 2040.
  • "This approval is an example of our unwavering commitment to this community by developing new, transformative therapeutic options for people experiencing advanced Parkinson's disease, their families, and care partners."
  • "It is vital that the Parkinson's community have more options that can help them manage their symptoms."

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Liver, Medical Subject Headings, Fungal infection, Marketing, European Commission, INN, Stomach, Allergy, Itraconazole, Saquinavir, ATC, Glass, Nelfinavir, Depression, Kidney disease, Bleeding, International, European, Megacolon, Disease, Urinary retention, Language, Muscle weakness, Urinary bladder, Inflammation, Nefazodone, Water, Peanut, Ulcerative colitis, Colitis, Ketoconazole, Ritonavir, Tablet, Hyperkinesia, Indinavir, CYP3A4, Xerostomia, Select, Committee, Urination, Patient, Liver disease, Atazanavir, Anatomy, Medicine, Clarithromycin, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on: 
Saturday, December 9, 2023
Patient, Cogent, OLE, MAS, Deficit spending, ISM, GIST, Fourth grade, Poster, Bleeding, American Society of Hematology, APEX, Disease, KIT, MD Anderson Cancer Center, Society, Stromal cell, SSM, PD, ASH, Mutation, VAF, Hyperkinesia, Part, PGIC, Webcast, Safety, University, PEAK, Dermatology, Pharmaceutical industry

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.

Key Points: 
  • Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.
  • Patients were enrolled with the following sub-types: 18 patients with indolent systemic mastocytosis (ISM) and two patients with smoldering systemic mastocytosis (SSM).
  • In patients with completed questionnaires:
    By week 12, bezuclastinib patients showed a median best improvement of 37% on MC-QoL vs. 24% for placebo patients.
  • Data from Part 1 of the Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) will be presented in a poster session at ASH on Monday, December 11, 2023 at ASH.

MarinHealth Interventional Cardiologists Are First on the West Coast to Perform Symplicity™ Renal Denervation Procedure Outside of a Clinical Trial

Retrieved on: 
Wednesday, December 13, 2023
Cardiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Clinical Trials, Exercise, Hypertension, Hyperkinesia, Patient, Food, Kidney, RDN, Weight loss, FDA, Blood pressure, Pharmaceutical industry, Reta, MD

MarinHealth interventional cardiologists treated the first patient with a revolutionary new renal denervation (RDN) procedure, now offered for patients with poorly controlled blood pressure.

Key Points: 
  • MarinHealth interventional cardiologists treated the first patient with a revolutionary new renal denervation (RDN) procedure, now offered for patients with poorly controlled blood pressure.
  • The procedure – also known as the Symplicity™ blood pressure procedure – is approved for use as an adjunctive treatment in patients with high blood pressure (or hypertension) when lifestyle changes and antihypertensive medications do not adequately control blood pressure.
  • A combination of lifestyle changes, like exercise and weight loss, and medication can help treat high blood pressure safely.
  • "Renal denervation can help reduce blood pressure in patients with a single, minimally invasive procedure and does not require a permanent implant.

Medtronic announces FDA approval of minimally invasive device to treat hypertension

Retrieved on: 
Friday, November 17, 2023
Hypertension, NYSE, Prevalence, RDN, Medtronic, Coronary, HTN, Patient, FDA, Kidney, Internal medicine, Stroke, University, Death, Hyperkinesia, Physician, Blood pressure, Pharmaceutical industry, Medicine

DUBLIN, Nov. 17, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity™ blood pressure procedure, for the treatment of hypertension. With this approval, Medtronic will immediately begin commercialization.

Key Points: 
  • Hypertension, or high blood pressure, is the leading modifiable cause of heart attack, stroke, and death, and its prevalence is notably worse in underserved U.S. populations.
  • These challenges speak to the possibility that patients may benefit from an adjunctive treatment option to better manage their blood pressure.
  • The approval of the Symplicity blood pressure procedure represents a significant milestone for physicians and patients in the treatment of hypertension."
  • The Medtronic Symplicity blood pressure procedure is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood pressure.

Researchers at Fermata to Study SAINT Neuromodulation for Treatment-Resistant Major Depression

Retrieved on: 
Wednesday, October 25, 2023
MRI, MDD, Health, Major depressive disorder, SAINT, Hyperkinesia, United, DSM-IV codes, Clinical trial, World Health Organization, OLO, ABPN, Depression, Patient, TRD, Pharmaceutical industry, Nursing, Fermata, Child

The prospective, multi-site open-label optimization study (OLO) is designed to further evaluate the effectiveness of the investigational SAINT Neuromodulation System for the treatment of adults with MDD.

Key Points: 
  • The prospective, multi-site open-label optimization study (OLO) is designed to further evaluate the effectiveness of the investigational SAINT Neuromodulation System for the treatment of adults with MDD.
  • The SAINT Neuromodulation System may yield a new form of personalized, focused neurostimulation in adults with major depression.
  • Treatment-resistant depression (TRD) can leave sufferers feeling like they are out of options," said Owen Scott Muir, M.D.
  • This study is the first time the SAINT Neuromodulation System has been studied at multiple sites in a large sample of individuals with major depression.

American Kidney Fund Launches Educational Awareness Campaigns for Two Rare Kidney Diseases

Retrieved on: 
Tuesday, September 26, 2023
Infection, Tissue, Kidney failure, AKF, Inflammation, Immunoglobulin A, Kidney, Antibody, Hyperkinesia, C3, New Brunswick neurological syndrome of unknown cause, Novartis, Patient, American Kidney Fund, Blood, Immune system, Glomerulopathy, Diagnosis, Health, Kidney disease, Disease, Pharmaceutical industry, IgA nephropathy

ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched educational awareness campaigns for two rare kidney diseases: complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN).

Key Points: 
  • ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched educational awareness campaigns for two rare kidney diseases: complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN).
  • The campaigns, sponsored by Novartis, provide patients with information about the diseases and connect them with resources to help them better understand and manage these conditions.
  • C3G and IgAN are two types of kidney diseases that are related to improper function of the immune system, which is your body's cells and tissues that fight infection.
  • The C3G and IgAN campaigns are part of AKF’s ongoing work to increase awareness and understanding of rare kidney diseases and ensure people with these conditions have access to critical resources.

OverActive Media Brings Home Gold at the 2023 Sponsorship Marketing Awards

Retrieved on: 
Friday, September 22, 2023
Toronto Ultra, 2018 Overwatch League Grand Finals, Bell, Call of Duty League, Senior, Life, SMCC, Marketing, Internet, Spinal muscular atrophies, Calendar, Ford, Organization, Visa, OverActive Media, Investment, Growth, Coca-Cola, Partnership, Sponsor (commercial), Hyperkinesia, OAM, Video game

Toronto Ultra Major III Professional Esports Tournament, Powered by Bell, Recognized in the Events and Festivals Category

Key Points: 
  • Toronto Ultra Major III Professional Esports Tournament, Powered by Bell, Recognized in the Events and Festivals Category
    TORONTO, Sept. 22, 2023 /CNW/ - OverActive Media (TSXV: OAM) (OTCQB: OAMCF), a global sports, media and entertainment company for today's generation of fans, along with its longstanding partner, Bell, won gold at the Sponsorship Marketing Council of Canada's (SMCC) 2023 Sponsorship Marketing Awards (SMAs).
  • Toronto Ultra Major III, Powered by Bell, broke new ground, setting the stage for future esports events in the city.
  • The award marks the second SMCC win for OverActive, with the first being Property of the Year for Toronto Ultra in 2021.
  • Launched in 2000 to recognize sponsorship marketing excellence, the SMAs have become a cornerstone of the SMCC and an anticipated event in the Canadian marketing calendar.

OverActive Media Unveils Global Content Creator Academy

Retrieved on: 
Thursday, September 7, 2023
COVID-19, OverActive Media, News, Risk, Regulation, Hyperkinesia, Risk management

With a reach of over 15 million, they represent a meaningful audience driver for OverActive and our partners," said Alyson Walker, Chief Commercial Officer, OverActive Media.

Key Points: 
  • With a reach of over 15 million, they represent a meaningful audience driver for OverActive and our partners," said Alyson Walker, Chief Commercial Officer, OverActive Media.
  • We're thrilled to make OverActive's Content Creator Academy official and to kick things off with such a diverse group."
  • Check out OverActive's Content Creator Academy at overactivemedia.com/content-creator-academy/ for the latest roster news.
  • OverActive does not intend, and does not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.